Insights from Basic Adjunctive Examinations of GCK-MODY, HNF1A-MODY, and Type 2 Diabetes: A Systemic Review and Meta-analysis

Overview

Journal J Diabetes

Specialty Endocrinology

Date 2023 May 25

PMID 37226652

Authors

Jing Liu

Xinhua Xiao

Qian Zhang

Miao Yu

Affiliations

Soon will be listed here.

Abstract

Background: Glucokinase maturity-onset diabetes of the young (GCK-MODY) is difficult to distinguish from other diabetic forms. This article aims to characterize the differences in results from routine examinations between GCK-MODY and hepatocyte nuclear factor 1-α (HNF1A)-MODY or type 2 diabetes (T2D) patients in different periods of diabetes.

Methods: Ovid Medline, Embase, and the Cochrane Library were searched up until October 9, 2022 for articles containing baseline characteristics of GCK-MODY, HNF1A-MOFY, and T2D, excluding pregnant women. The pooled standardized mean differences were derived using a random-effects model.

Results: Compared to HNF1A-MODY, GCK-MODY patients had lower indicators of glucose metabolism. Total triglycerides (TG) (-0.93 [-1.66, -0.21] mmol/l) were consistently lower in GCK-MODY patients in the all-family-members subgroup analysis. Compared to T2D, GCK-MODY patients were younger at diagnosis and had lower body mass index (BMI), lower high-sensitivity C-reactive protein (hsCRP) (-0.60 [-0.75, -0.44] mg/l), lower fasting C-peptide (FCP), and lower 2-hour postprandial glucose (2-h PG). Indicators of glycated hemoglobin (HbA1c) and fasting blood glucose (FPG) were consistently lower in subgroup studies with all family members of GCK-MODY patients as well.

Conclusions: Lower HbA1c, FPG, 2-h PG, and change in 2-h PG may help to diagnose GCK-MODY differentially from HNF1A-MODY at an early stage, and lower TG may strengthen such a diagnosis in the follow-up stages. Younger age combined with lower BMI, FCP, hsCRP, and 2-h PG may be useful to distinguish GCK-MODY from MODY-like T2D, whereas results of glucose metabolism indicators such as HbA1c and FPG may not help physicians until after a long follow-up period.

Citing Articles

Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.

Liu J, Xiao X, Zhang Q, Yu M J Diabetes. 2023; 15(6):519-531.

PMID: 37226652 PMC: 10270746. DOI: 10.1111/1753-0407.13390.

References

Fu J, Ping F, Wang T, Liu Y, Wang X, Yu J . A Clinical Prediction Model to Distinguish Maturity-Onset Diabetes of the Young From Type 1 and Type 2 Diabetes in the Chinese Population. Endocr Pract. 2021; 27(8):776-782. DOI: 10.1016/j.eprac.2021.05.002. View

Steele A, Shields B, Wensley K, Colclough K, Ellard S, Hattersley A . Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014; 311(3):279-86. DOI: 10.1001/jama.2013.283980. View

Passanisi S, Salzano G, Bombaci B, Lombardo F . Clinical and genetic features of maturity-onset diabetes of the young in pediatric patients: a 12-year monocentric experience. Diabetol Metab Syndr. 2021; 13(1):96. PMC: 8424812. DOI: 10.1186/s13098-021-00716-6. View

Yorifuji T, Fujimaru R, Hosokawa Y, Tamagawa N, Shiozaki M, Aizu K . Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes. 2011; 13(1):26-32. DOI: 10.1111/j.1399-5448.2011.00827.x. View

Bacon S, Kyithar M, Schmid J, Rizvi S, Bonner C, Graf R . Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward. BMC Endocr Disord. 2012; 12:13. PMC: 3433346. DOI: 10.1186/1472-6823-12-13. View

Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G . Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J. 1990; 9(13):4467-75. PMC: 552239. DOI: 10.1002/j.1460-2075.1990.tb07897.x. View

Millan A, Trobo S, De Dios A, Cerrato Garcia M, Perez M, Cerrone G . MODY patients exhibit shorter telomere length than non-diabetic subjects. Diabetes Metab Res Rev. 2020; 37(2):e3374. DOI: 10.1002/dmrr.3374. View

Pacaud D, Schwandt A, de Beaufort C, Casteels K, Beltrand J, Birkebaek N . A description of clinician reported diagnosis of type 2 diabetes and other non-type 1 diabetes included in a large international multicentered pediatric diabetes registry (SWEET). Pediatr Diabetes. 2016; 17 Suppl 23:24-31. DOI: 10.1111/pedi.12426. View

Huang X, Gong S, Ma Y, Cai X, Zhou L, Luo Y . Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes. J Diabetes Res. 2018; 2018:7842064. PMC: 6093029. DOI: 10.1155/2018/7842064. View

10.

Shi J, Luo D, Weng H, Zeng X, Lin L, Chu H . Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020; 11(5):641-654. DOI: 10.1002/jrsm.1429. View

11.

Dusatkova P, Pavlikova M, Spirkova A, Elblova L, Janickova Zdarska D, Rozenkova K . Quality of Life and Treatment Satisfaction in Participants with Maturity-Onset Diabetes of the Young: A Comparison to Other Major Forms of Diabetes. Exp Clin Endocrinol Diabetes. 2020; 130(2):85-93. DOI: 10.1055/a-1200-1482. View

12.

Elias-Assad G, Saab R, Molnes J, Hess O, Abu-Ras R, Darawshi H . Maturity onset diabetes of the young type 2 (MODY2): Insight from an extended family. Diabetes Res Clin Pract. 2021; 175:108791. DOI: 10.1016/j.diabres.2021.108791. View

13.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

14.

Barrio R, Bellanne-Chantelot C, Moreno J, Morel V, Calle H, Alonso M . Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab. 2002; 87(6):2532-9. DOI: 10.1210/jcem.87.6.8530. View

15.

Fendler W, Borowiec M, Antosik K, Szadkowska A, Deja G, Jarosz-Chobot P . HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults. Clin Endocrinol (Oxf). 2011; 75(3):321-7. DOI: 10.1111/j.1365-2265.2011.04052.x. View

16.

Goksen D, Yesilkaya E, Ozen S, Kor Y, Eren E, Korkmaz O . Molecular Diagnosis of Monogenic Diabetes and Their Clinical/Laboratory Features in Turkish Children. J Clin Res Pediatr Endocrinol. 2021; 13(4):433-438. PMC: 8638634. DOI: 10.4274/jcrpe.galenos.2021.2021.0056. View

17.

Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T . Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009; 26(5):466-73. DOI: 10.1111/j.1464-5491.2009.02720.x. View

18.

Stankute I, Verkauskiene R, Blouin J, Klee P, Dobrovolskiene R, Danyte E . Systematic Genetic Study of Youth With Diabetes in a Single Country Reveals the Prevalence of Diabetes Subtypes, Novel Candidate Genes, and Response to Precision Therapy. Diabetes. 2020; 69(5):1065-1071. DOI: 10.2337/db19-0974. View

19.

Chevre J, Hani E, Boutin P, Vaxillaire M, Blanche H, Vionnet N . Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia. 1998; 41(9):1017-23. DOI: 10.1007/s001250051025. View

20.

Spegel P, Ekholm E, Tuomi T, Groop L, Mulder H, Filipsson K . Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2). Diabetes. 2012; 62(2):653-61. PMC: 3554352. DOI: 10.2337/db12-0827. View